Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
Status:
Completed
Trial end date:
2020-06-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of niraparib in participants
with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary
peritoneal cancer who have received 3 or 4 previous chemotherapy regimens.